Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings

TY - JOUR

T1 - Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks

T2 - COMPACT subgroup findings

AU - COMPACT Investigators

AU - Craig, Timothy

AU - Lumry, William

AU - Cicardi, M.

AU - Zuraw, B.

AU - Bernstein, Jonathan A.

AU - Anderson, John

AU - Jacobs, Joshua

AU - Riedl, Marc A.

AU - Manning, Michael E.

AU - Banerji, Aleena

AU - Gower, Richard G.

AU - Caballero, Teresa

AU - Farkas, Henriette

AU - Feuersenger, Henrike

AU - Jacobs, Iris

AU - Machnig, Thomas

AU - Longhurst, Hilary

N1 - Funding Information: This study was funded by CSL Behring.Conflicts of interest: T. Craig reports grants, personal fees, and other from Shire; grants, personal fees and other from CSL Behring; grants and other from BioCryst; and other from Hereditary Angioedema Association of America, outside the submitted work. W. Lumry has received research grants and consulting fees/honorarium from CSL Behring and Shire/ViroPharma and Pharming; consulting fees/honorarium from BioCryst and Adverum; support for travel to meetings for the study or other purposes from CSL Behring and the United States Hereditary Angioedema Association; and fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like from BioCryst. M. Cicardi has received research grants, is an advisory board member, and has served as a speaker for Shire and Pharming; he has served as an advisory board member and speaker for CSL Behring and BioCryst. B. Zuraw has served as a consultant for CSL Behring, Shire, BioCryst, Adverum, Novartis, Sanofi, and Genentech; he has worked in a research support capacity for Ionis. J. A. Bernstein reports grants and personal fees from Shire; grants and personal fees from CSL Behring; grants and personal fees from Pharming; grants and personal fees from BioCryst, from HAEA medical advisory board, during the conduct of the study; grants and personal fees from Novartis/Genentech; and grants and personal fees from AstraZeneca, outside the submitted work. J. Anderson reports personal fees and other from Shire; other from Dyax; personal fees and other from CSL Behring; personal fees from Pharming; and other from BioCryst, outside the submitted work. J. Jacobs has received research grants, consulting fees, and honoraria from Shire plc, CSL Behring, Pharming, and BioCryst. M. A. Riedl has served in a research support capacity for BioCryst, CSL Behring, Pharming, and Shire; he has received consulting fees from BioCryst, CSL Behring, Shire, Pharming, Kalvista, and Adverum; and honorarium for speaking from CSL Behring, Pharming, and Shire. M. E. Manning reports grants and personal fees from Shire; grants from Dyax; grants and personal fees from CSL Behring; personal fees from Pharming; and grants from BioCryst, outside the submitted work. A. Banerji has received research grants from Shire and BioCryst; she served on advisory boards for Shire, BioCryst, CSL Behring, and Pharming. R. G. Gower reports grants and personal fees from CSL Behring; grants and personal fees from Shire/Dyax; grants from BioCryst; and grants and personal fees from Pharming/Salix, outside the submitted work. T. Caballero has received speaker fees from CSL Behring, Novartis, and Shire; consultancy fees from BioCryst, CSL Behring, Novartis, Octapharma, and Shire; funding for travel and meeting attendance from CSL Behring, Novartis, and Shire; and has participated in clinical trials/registries for BioCryst, CSL Behring, Novartis, and Shire. She is a researcher for the IdiPaz program promoting research activities. H. Farkas has received research support from Shire; is on the advisory boards for CSL Behring, Shire, BioCryst, and Swedish Orphan Biovitrum (SOBI); and has received consultancy fee from CSL Behring, Shire, BioCryst, and SOBI and speaker fee from CSL Behring, Pharming Group, and SOBI. H. Feuersenger reports personal fees from employment by CSL Behring (funding company), outside the submitted work. I. Jacobs reports personal fees from employment by CSL Behring (funding company), outside the submitted work. T. Machnig reports personal fees from employment by CSL Behring (funding company), outside the submitted work. H. Longhurst has received consultancy fees, educational support, and/or research funding from Adverum, BioCryst, CSL Behring, Pharming, and Shire, outside the submitted work.Writing assistance was provided by Churchill Communications (Maplewood, NJ), and funded by CSL Behring. Funding Information: This study was funded by CSL Behring . Funding Information: This study was funded by CSL Behring.Conflicts of interest: T. Craig reports grants, personal fees, and other from Shire; grants, personal fees and other from CSL Behring; grants and other from BioCryst; and other from Hereditary Angioedema Association of America, outside the submitted work. W. Lumry has received research grants and consulting fees/honorarium from CSL Behring and Shire/ViroPharma and Pharming; consulting fees/honorarium from BioCryst and Adverum; support for travel to meetings for the study or other purposes from CSL Behring and the United States Hereditary Angioedema Association; and fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like from BioCryst. M. Cicardi has received research grants, is an advisory board member, and has served as a speaker for Shire and Pharming; he has served as an advisory board member and speaker for CSL Behring and BioCryst. B. Zuraw has served as a consultant for CSL Behring, Shire, BioCryst, Adverum, Novartis, Sanofi, and Genentech; he has worked in a research support capacity for Ionis. J. A. Bernstein reports grants and personal fees from Shire; grants and personal fees from CSL Behring; grants and personal fees from Pharming; grants and personal fees from BioCryst, from HAEA medical advisory board, during the conduct of the study; grants and personal fees from Novartis/Genentech; and grants and personal fees from AstraZeneca, outside the submitted work. J. Anderson reports personal fees and other from Shire; other from Dyax; personal fees and other from CSL Behring; personal fees from Pharming; and other from BioCryst, outside the submitted work. J. Jacobs has received research grants, consulting fees, and honoraria from Shire plc, CSL Behring, Pharming, and BioCryst. M. A. Riedl has served in a research support capacity for BioCryst, CSL Behring, Pharming, and Shire; he has received consulting fees from BioCryst, CSL Behring, Shire, Pharming, Kalvista, and Adverum; and honorarium for speaking from CSL Behring, Pharming, and Shire. M. E. Manning reports grants and personal fees from Shire; grants from Dyax; grants and personal fees from CSL Behring; personal fees from Pharming; and grants from BioCryst, outside the submitted work. A. Banerji has received research grants from Shire and BioCryst; she served on advisory boards for Shire, BioCryst, CSL Behring, and Pharming. R. G. Gower reports grants and personal fees from CSL Behring; grants and personal fees from Shire/Dyax; grants from BioCryst; and grants and personal fees from Pharming/Salix, outside the submitted work. T. Caballero has received speaker fees from CSL Behring, Novartis, and Shire; consultancy fees from BioCryst, CSL Behring, Novartis, Octapharma, and Shire; funding for travel and meeting attendance from CSL Behring, Novartis, and Shire; and has participated in clinical trials/registries for BioCryst, CSL Behring, Novartis, and Shire. She is a researcher for the IdiPaz program promoting research activities. H. Farkas has received research support from Shire; is on the advisory boards for CSL Behring, Shire, BioCryst, and Swedish Orphan Biovitrum (SOBI); and has received consultancy fee from CSL Behring, Shire, BioCryst, and SOBI and speaker fee from CSL Behring, Pharming Group, and SOBI. H. Feuersenger reports personal fees from employment by CSL Behring (funding company), outside the submitted work. I. Jacobs reports personal fees from employment by CSL Behring (funding company), outside the submitted work. T. Machnig reports personal fees from employment by CSL Behring (funding company), outside the submitted work. H. Longhurst has received consultancy fees, educational support, and/or research funding from Adverum, BioCryst, CSL Behring, Pharming, and Shire, outside the submitted work.Writing assistance was provided by Churchill Communications (Maplewood, NJ), and funded by CSL Behring. This study was funded by CSL Behring. Conflicts of interest: T. Craig reports grants, personal fees, and other from Shire; grants, personal fees and other from CSL Behring; grants and other from BioCryst; and other from Hereditary Angioedema Association of America, outside the submitted work. W. Lumry has received research grants and consulting fees/honorarium from CSL Behring and Shire/ViroPharma and Pharming; consulting fees/honorarium from BioCryst and Adverum; support for travel to meetings for the study or other purposes from CSL Behring and the United States Hereditary Angioedema Association; and fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like from BioCryst. M. Cicardi has received research grants, is an advisory board member, and has served as a speaker for Shire and Pharming; he has served as an advisory board member and speaker for CSL Behring and BioCryst. B. Zuraw has served as a consultant for CSL Behring, Shire, BioCryst, Adverum, Novartis, Sanofi, and Genentech; he has worked in a research support capacity for Ionis. J. A. Bernstein reports grants and personal fees from Shire; grants and personal fees from CSL Behring; grants and personal fees from Pharming; grants and personal fees from BioCryst, from HAEA medical advisory board, during the conduct of the study; grants and personal fees from Novartis/Genentech; and grants and personal fees from AstraZeneca, outside the submitted work. J. Anderson reports personal fees and other from Shire; other from Dyax; personal fees and other from CSL Behring; personal fees from Pharming; and other from BioCryst, outside the submitted work. J. Jacobs has received research grants, consulting fees, and honoraria from Shire plc, CSL Behring, Pharming, and BioCryst. M. A. Riedl has served in a research support capacity for BioCryst, CSL Behring, Pharming, and Shire; he has received consulting fees from BioCryst, CSL Behring, Shire, Pharming, Kalvista, and Adverum; and honorarium for speaking from CSL Behring, Pharming, and Shire. M. E. Manning reports grants and personal fees from Shire; grants from Dyax; grants and personal fees from CSL Behring; personal fees from Pharming; and grants from BioCryst, outside the submitted work. A. Banerji has received research grants from Shire and BioCryst; she served on advisory boards for Shire, BioCryst, CSL Behring, and Pharming. R. G. Gower reports grants and personal fees from CSL Behring; grants and personal fees from Shire/ Dyax; grants from BioCryst; and grants and personal fees from Pharming/Salix, outside the submitted work. T. Caballero has received speaker fees from CSL Behring, Novartis, and Shire; consultancy fees from BioCryst, CSL Behring, Novartis, Octapharma, and Shire; funding for travel and meeting attendance from CSL Behring, Novartis, and Shire; and has participated in clinical trials/registries for BioCryst, CSL Behring, Novartis, and Shire. She is a researcher for the IdiPaz program promoting research activities. H. Farkas has received research support from Shire; is on the advisory boards for CSL Behring, Shire, BioCryst, and Swedish Orphan Biovitrum (SOBI); and has received consultancy fee from CSL Behring, Shire, BioCryst, and SOBI and speaker fee from CSL Behring, Pharming Group, and SOBI. H. Feuersenger reports personal fees from employment by CSL Behring (funding company), outside the submitted work. I. Jacobs reports personal fees from employment by CSL Behring (funding company), outside the submitted work. T. Machnig reports personal fees from employment by CSL Behring (funding company), outside the submitted work. H. Longhurst has received consultancy fees, educational support, and/or research funding from Adverum, BioCryst, CSL Behring, Pharming, and Shire, outside the submitted work. Funding Information: Writing assistance was provided by Churchill Communications (Maplewood, NJ), and funded by CSL Behring .

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85061569400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061569400&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2019.01.007

DO - 10.1016/j.jaip.2019.01.007

M3 - Article

C2 - 30660873

AN - SCOPUS:85061569400

VL - 7

SP - 2035

EP - 2038

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 6

ER -